| 主权项 |
1. A pharmaceutical composition comprising a LMWH preparation, wherein the LMWH preparation has the following characteristics:
(a) a weight average chain molecular weight between 3,500 and 8,000 Da; (b) anti-Xa activity of less than 20 IU/mg and anti-IIa activity of 20IU/mg or less; (c) greater than 5% and less than 50% glycol split uronic acid residue (UG) in the preparation; and one or more buffering agents selected from the group consisting of a citrate buffer, a phosphate buffer, a histidine buffer, a maleate buffer, a succinate buffer, an acetate buffer, a malate buffer, or any combination thereof. |
